Triple-negative breast cancers (TNBCs) account for ~15% of all instances of mammary tumors without expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to triple-negative breast carcinoma.